Enhanced delivery epinephrine compositions
Pharmaceutical compositions having enhanced active component permeation properties are described.
1. A pharmaceutical composition for oral delivery, comprising:
a mucoadhesive polymeric matrix;
a pharmaceutically active component including epinephrine, a pharmaceutically acceptable salt or ester thereof in the polymeric matrix; and
an adrenergic receptor interacter that enhances permeation of the epinephrine, pharmaceutically acceptable salt or ester thereof through mucosal barrier by utilizing at least a paracellular transport route or mechanism, wherein the composition is a film, the pharmaceutically active component being contained in the polymeric matrix of the film.
2. The pharmaceutical composition according to claim 1 , further comprising a permeation enhancer in addition to the adrenergic receptor interacter.
3. The pharmaceutical composition according to claim 2 , wherein the adrenergic receptor interacter is linoleic acid.
4. The pharmaceutical composition of claim 2 , wherein the permeation enhancer and the pharmaceutically active component are contained in discrete layers of the film.
5. The pharmaceutical composition according to claim 1 , wherein the adrenergic receptor interacter is farnesol.
6. The pharmaceutical composition according to claim 1 , wherein the adrenergic receptor interacter is eugenol or eugenol acetate.
7. The pharmaceutical composition according to claim 1 , wherein the adrenergic receptor interacter is a cinnamic acid, cinnamic acid ester, cinnamic aldehyde,. or hydrocinnamic acid.
8. The pharmaceutical composition according to claim 1 , wherein the adrenergic receptor interacter is chavicol.
9. The pharmaceutical composition according to claim 1 , wherein the adrenergic receptor interacter is safrole.
10. The pharmaceutical composition according to claim 1 , wherein the adrenergic receptor interacter is a phytoextract.
11. The pharmaceutical composition according to claim 10 , wherein the phytoextract includes an essential oil extract of a clove plant.
12. The pharmaceutical composition according to claim 10 , wherein the phytoextract includes an essential oil extract of a leaf of a clove plant.
13. The pharmaceutical composition according to claim 10 , wherein the phytoextract includes an essential oil extract of a flower bud of a clove plant.
14. The pharmaceutical composition according to claim 10 , wherein the phytoextract includes an essential oil extract of a stem of a clove plant.
15. The pharmaceutical composition according to claim 10 , wherein the phytoextract is synthetic or biosynthetic.
16. The pharmaceutical composition according to claim 10 , wherein the phytoextract includes 40-95% eugenol.
17. The pharmaceutical composition according to claim 1 , wherein the adrenergic receptor interacter includes a terpene or a sesquiterpene.
18. The pharmaceutical composition according to claim 1 , wherein the polymer matrix includes a polymer.
19. The pharmaceutical composition according to claim 18 , wherein the polymer is a water soluble polymer.
20. The pharmaceutical composition according to claim 18 , wherein the polymer includes a polyethylene oxide.
21. The pharmaceutical composition according to claim 18 , wherein the polymer includes a cellulosic polymer selected from the group of: hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, methylcellulose, and carboxymethyl cellulose.
22. The pharmaceutical composition according to claim 18 , wherein the polymeric matrix comprises a cellulosic polymer, polyethylene oxide and polyvinyl pyrrolidone, polyethylene oxide and a polysaccharide, polyethylene oxide, hydroxypropyl methylcellulose and a polysaccharide, or polyethylene oxide, hydroxypropyl methylcellulose, polysaccharide, and polyvinylpyrroli done.
23. The pharmaceutical composition according to claim 18 , wherein the polymeric matrix comprises at least one polymer selected from the group of: pullulan, polyvinyl pyrrolidone, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, ethylene oxide-propylene oxide copolymers, collagen, albumin, poly-amino acids, polyphosphazenes, polysaccharides, chitin, and chitosan.
24. The pharmaceutical composition according to claim 1 , further comprising a stabilizer.
25. The pharmaceutical composition according to claim 1 , wherein the polymeric matrix comprises a dendritic polymer or a hyperbranched polymer.
26. A device comprising
a housing that holds an amount of a pharmaceutical composition for oral delivery of claim 1 and
an opening that dispenses a predetermined amount of the pharmaceutical composition.
27. A pharmaceutical composition for oral delivery comprising
a pharmaceutically active component including epinephrine, a pharmaceutically acceptable salt or ester thereof; and
an adrenergic receptor interacter that enhances permeation of the epinephrine, pharmaceutically acceptable salt or ester thereof through a mucosal barrier by utilizing at least a paracellular transport route or mechanism, wherein the pharmaceutical composition is a chewable or gelatin based dosage form, spray, gum, gel, cream, tablet, liquid or film.
28. A method of making a pharmaceutical composition for oral delivery comprising:
combining an adrenergic receptor interacter with a pharmaceutically active component including epinephrine, a pharmaceutically acceptable salt or ester thereof, wherein the adrenergic receptor interacter enhances permeation of the epinephrine, a pharmaceutically acceptable salt or ester thereof through a mucosal barrier by utilizing at least a paracellular transport route or mechanism, and
forming a pharmaceutical composition including the adrenergic receptor interacter and the pharmaceutically active component,
wherein the pharmaceutical composition is a film, the pharmaceutically active component being contained in a mucoadhesive polymeric matrix of the film.